Association of Long-acting Bronchodilator Use with Cardiovascular Adverse Events in Patients with Asthma: A Population-based Cohort Study.
文献摘要
Background A recent meta-analysis of randomized controlled trials found that long-acting bronchodilator use was associated with cardiovascular adverse events (AEs) leading to treatment discontinuation in asthma, although the certainty of evidence was low. Objective To evaluate the cardiovascular safety of long-acting bronchodilators in a real-world asthma population. Methods This population-based cohort study used UK Biobank data from patients with asthma (2006-2010). Exposure was categorized into three mutually exclusive groups: LABA alone, LAMA alone, or combined LABA/LAMA therapy. The primary outcome was a composite of cardiovascular AEs, including coronary heart disease, arrhythmia, hypertension, heart failure, and cerebrovascular disease. Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). Pre-specified subgroup analyses and interaction tests were performed. Results A total of 14,677 patients were included (median follow-up 14.68 years). Long-acting bronchodilator use was associated with an increased risk of total cardiovascular AEs (HR: 1.08, 95% CI: 1.02-1.15). This was primarily driven by arrhythmia (HR: 1.23, 95% CI: 1.06-1.42), heart failure (HR: 1.30, 95% CI: 1.02-1.65), and cerebrovascular disease (HR: 1.35, 95% CI: 1.02-1.79). When stratified by regimen, the association was confined to the LABA group (HR: 1.07, 95% CI: 1.001-1.13) and the combined group (HR: 1.32, 95% CI: 1.09-1.59). The association was more pronounced in patients using short-acting bronchodilators (HR: 1.15, 95% CI: 1.07-1.23; interaction P = 0.004). Conclusions The observed positive associations are more plausibly attributable to confounding rather than to a causal drug effect. Future research should prioritize new-user designs to clarify whether these signals are drug-specific or confounded by disease severity.